LOS ANGELES--(BUSINESS WIRE)--The Lundquist Institute received unanimous approval from the Los Angeles County Board of Supervisors to begin development of a 15-acre biotech park, which will serve as a hub and catalyst for the region’s rapidly-developing bioscience industry.
In addition to established companies, the tech park will serve early-stage biotech companies, many of whom currently choose to establish themselves in known life science hubs such as Cambridge, La Jolla and the San Francisco Bay Area. This one-of-a-kind campus, comprising a major medical center, a renowned research institute, in addition to the biotech park, provides a rare opportunity for the development of world-class facilities in a convenient central location, endowing Los Angeles County with an entirely new capacity to attract and retain life science startups.
The Lundquist Institute’s biotech park will occupy a site on the western portion of the County-owned Harbor-UCLA Medical Center campus near Torrance, and will replace several World War II-era barracks from the hospital’s days as a military facility. In the first phase of the master plan, The Lundquist Institute will oversee the construction of three buildings totaling up to 250,000 square feet, with top-of-the-line laboratory, manufacturing and office space.
“This is a truly momentous occasion for The Lundquist Institute, as we can now move full speed ahead on creating a campus that provides bioscience innovations a soup-to-nuts opportunity all on one 72 acre campus, from the medical center, to the research institute, to our bioscience incubator and finally, the tech park,” said David Meyer, PhD, President and CEO of The Lundquist Institute. “I am deeply grateful for the vision of the Board, particularly Supervisor Mark Ridley-Thomas, who understands the urgency of developing a bigger life science industry in the County of Los Angeles. This campus will be a hub for innovation and a testament to that vision.”
Through the commitment of Supervisor Ridley-Thomas, the Board of Supervisors, is showing its long-term commitment to bioscience by granting The Lundquist Institute a 55-year lease with two 20-year extension options to develop the new campus. The Lundquist Institute is now screening potential developers that demonstrate the experience and expertise to create facilities that will give burgeoning life science companies the confidence needed to set up shop in the South Bay.
“The Lundquist Institute is a transformational asset to the region, and I am proud it will become the home of this revolutionary biotech park,” said Supervisor Mark Ridley-Thomas. “I have long been a proponent of establishing a bioscience hub in Los Angeles, and this is concrete and catalytic progress to realize that dream. The bioscience boom is on its way to LA!”
The Lundquist Institute has a national reputation for the discoveries and innovations, including the development of paramedic training and the first FDA-approved treatment for sickle cell disease in more than 20 years. Last year, the institute opened an incubator, BioLabs at The Lundquist Institute, which is now home to more than 20 early-stage startups.
Developing the biotech park will allow The Lundquist Institute to take the next step and provide a home for the full cycle of innovation, from an idea generated in its labs to a startup at the incubator to a mature company with a permanently situated at the tech park—and clinical trial and other capabilities tied to a full-service, adjacent medical center.
The biotech park’s central location on the County-owned campus near Torrance provides growing life science companies easy access to one of the world’s busiest ports, a major international airport and principal rail and freight lines to deliver product worldwide. Los Angeles County’s excellent universities continue to produce world-class scientists, who will now be able to avail themselves of top-tier facilities and quality of life in making the decision as to where to establish their companies.
About The Lundquist Institute: Research with Reach
The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 68-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, The Lundquist Institute is poised to serve as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous orphan diseases, and is responsible for innovations including the first FDA-approved treatment for sickle cell disease in 20 years. Find out more at https://lundquist.org.
